Article

Screening for EGFR mutations in lung cancer.

Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain.
Discovery medicine 12/2009; 8(43):181-4. pp.181-4
Source: PubMed

ABSTRACT Certain mutations in the epidermal growth factor receptor (EGFR) gene confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small cell lung cancer. Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment.

0 0
 · 
1 Bookmark
 · 
50 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

Certain mutations
 
erlotinib
 
hypersensitivity
 
non-small cell lung cancer
 
tyrosine kinase inhibitors gefitinib